Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life

Painful Diabetic Peripheral Neuropathy Clinical Trial

— BLOSSOM  

Official title:

Efficacy of Pregabalin and Duloxetine in Patients With Painful Diabetic Peripheral Neuropathy (PDPN): the Effect of Pain on Cognitive Function, Sleep and Quality of Life (BLOSSOM)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04246619
• Other study ID #: KCT 11/2017
• Secondary ID: 2017-004341-24
• Status: Terminated
• Phase: Phase 4
• Start date: November 12, 2019
• Est. completion date: December 21, 2021

Study information

• Verified date: March 2022
• Source: KRKA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective and the purpose of the trial is to: assess the efficacy of Pregabalin Krka and Dulsevia® in patients with PDPN, investigate the effect of Pregabalin Krka and Dulsevia® on pain and on quality of life (QOL), depression symptoms, cognitive functions, sleep quality and daytime sleepiness and assess the safety of Pregabalin Krka and Dulsevia® in patients with PDPN.

During the 3 months (12 weeks) 5 visits and 2 phone calls are planned.

After the ICF signature and before therapy is allocated, a screening procedure is carried out to verify eligibility: laboratory analyses (concentrations of TSH, vitamin B12, folic acid, glucose, HbA1c, pregnancy test for women of childbearing potential), assessment of PDPN (with questionnaire DN4), assessment of cognition (with questionnaire MoCA), habits, medical history (medical/surgical history and concomitant diseases, previous and/or existing therapy of pain in PDPN, concomitant medications) with measurements and evaluation of pain according to VAS.

On Visit 2 investigator checks the results of laboratory tests, of pregnancy test, measures vital signs, evaluates pain in PDPN according to VAS, checks previous analgesic therapy and concomitant medications.

If patient meets all inclusion and exclusion criteria, he/she is eligible and will be randomly assigned (automatically through electronic version of case report form (eCRF) into two therapy groups (treatment arms) - tretament with Pregabalin Krka OR treatment with Dulsevia®.

Investigator performs assessments of: QoL, sleep quality and daytime sleepiness, depression and adverse events.

At Visit 3, compliance monitoring is done, pain intensity in PDPN by VAS is evaluated, concomitant therapy is checked, vital signs are measured, doses of IMP are adjusted and adverse events assessment are carried out.

At Visit 4, pregnancy test for women of childbearing potential and compliance monitoring are carried out; concomitant medications are checked, vital signs are measured, pain intensity in PDPN by VAS is evaluated, IMP are adjusted and assessment of adverse events is carried out.

At Visit 5 investigator performs again assessments of: QoL, sleep quality and daytime sleepiness, depression, cognition and PDPN. Evaluation of the pain intensity in PDPN by VAS and assessment of the adverse events should be performed. Pregnancy test for women of childbearing potential is carried out.

Description:

During the 3 months (12 weeks) 5 visits and 2 phone calls are planned.

Procedures and administration:

On arrival at the trial site at Visit 1 the patient receives the complete information on the trial procedures. The patient confirms his decision to participate by signing the informed consent form (ICF). After the ICF signature and before therapy is allocated, a screening procedure is carried out to verify eligibility: laboratory analyses (concentrations of TSH, vitamin B12, folic acid, glucose, HbA1c, pregnancy test for women of childbearing potential), assessment of PDPN (with questionnaire DN4), assessment of cognition (with questionnaire MoCA), habits, medical history (medical/surgical history and concomitant diseases, previous and/or existing therapy of pain in PDPN, concomitant medications) with measurements and evaluation of pain according to VAS.

Patient is instructed not to take any PDPN medication and/or analgesics, if existing on a day of Visit 2.

Information obtained at Visit 1 is input in the eCRF.

Visit 2 (initial baseline visit): 0-7 days after Visit 1

Investigator checks the results of laboratory tests, of pregnancy test, measures vital signs (heart rate, blood pressure), evaluates pain in PDPN according to VAS (separate assessments of current pain intensity, average pain intensity in last 24-h, worst pain intensity in last 24-h, average pain intensity in last 4 weeks and worst pain intensity in last 4 weeks), checks previous analgesic therapy and concomitant medications.

If patient meets all inclusion and exclusion criteria, he/she is eligible and will be randomly assigned (automatically through electronic version of case report form (eCRF) into two therapy groups (treatment arms).

Investigator performs assessments of: QoL (with questionnaire SF-36), sleep quality and daytime sleepiness (with questionnaires ISI and ESS), depression (with questionnaire MDI) and adverse events.

Administration:

Eligible screened patients are randomly assigned into two therapy groups (treatment arms):

ARM 1: treatment with pregabalin (Pregabalin Krka) or ARM 2: treatment with duloxetine (Dulsevia®).

Each patient receives a Patient diary number 1, including the doses of Pregabalin Krka or Dulsevia® (depending on randomization) from Visit 2 (day 1) till Phone call 1, scales for assessing the pain and with the date of Phone call 1.

Treatment during PERIOD 1 (FLEXIBLE-DOSE REGIMEN during the first 14 days (±3 days) in order to allow the investigator to give each patient an optimal dose of IMP.

• ARM 1: pregabalin (Pregabalin Krka 25-150 mg/ day) FLEXIBLE-DOSE REGIMEN. Investigator can choose total Pregabalin Krka daily dose: 25 mg/day, 50 mg/day, 75 mg/day, 150 mg/day or 300 mg/day (from Phone call 1 further on)

• ARM 2: duloxetine (Dulsevia® 30-60 mg/ day) FLEXIBLE-DOSE REGIMEN:

Investigator can choose total Dulsevia® daily dose: 30 mg/day or 60 mg/day

At the Visit 2, RM is given to each patient to cover the treatment till the next Visit 3.

Phone call 1: week 1 (± 3 days) At week 1 (7 ± 3 days after Visit 2) investigator calls the patient by phone and ask him or her about possible adverse events and to evaluate the pain intensity in PDPN by VAS which is a part of Patient diary 1.

Investigator can adjust the dose of IMP during phone call:

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) is NOT achieved, the investigator can increase the dose;

• if bothersome adverse event occurs the investigator can decrease the dose (if possible).

The investigator also ask the patient if he or she is taking the IMP appropriately (according to investigator's instructions).

NOTE: On the next visit (Visit 3; 14 ± 3 days after Visit 2) following daily doses should be achieved by each patient:

• ARM 1: Total Pregabalin Krka daily dose: MINIMUM dose 150 mg/day

• ARM 2: Total Dulsevia daily dose: MINIMUM dose 60 mg/day

Visit 3: week 2 (14 ± 3 days after Visit 2) At Visit 3, compliance monitoring is done, pain intensity in PDPN by VAS is evaluated, concomitant therapy is checked, vital signs are measured, doses of IMP are adjusted and adverse events assessment are carried out.

Investigator collects the Patient Diary 1. Data in Patient Diary 1 are checked.Treatment during PERIOD 2 (it lasts 6 weeks)

Treatment options:

ARM 1: pregabalin (Pregabalin Krka) Investigator can choose: total Pregabalin Krka daily dose: 150 mg/day or 300 mg/day or 600 mg/day

NOTE:

If in the opinion of the investigator the minimum IMP dose of 150 mg of Pregabalin Krka/ 60 mg of Dulsevia® can not be reached after Visit 3, the patient must be excluded from the trial.

ARM 2: duloxetine (Dulsevia®)

Investigator can choose:

• total Dulsevia® daily dose*: 60 mg/day or 90 mg/day* or total Dulsevia® daily dose**:

120 mg/day

• once daily dosing by using available dosages. **the daily dose will be achieved with two devided doses of Dulsevia® by using available dosages.

ARM 1: pregabalin (Pregabalin Krka)

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is achieved during period 1, further treatment with Pregabalin Krka 150 mg/day or 300 mg/day in the period 2 is required.

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is NOT achieved, further treatment with a dose of:

• 150 mg/day (if patient was till now treated with equal dose) or 300 mg/day (if patient was till now treated with equal dose to 150 mg or 300 mg) or 600 mg/day (if patient was till now treated with equal dose to 300 mg) is required.

ARM 2: duloxetine (Dulsevia®)

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is achieved further treatment with Dulsevia® 60 mg/day in the period 2 is required.

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with baseline is NOT achieved, further treatment with the dose of:

• Dulsevia® 60 mg/day (if patient was till now treated with equal dose) or Dulsevia® 90 mg/day (if patient was till now treated with lower dose) or Dulsevia® 120 mg/day (if patient was till now treted with lower dose) is required.

At the Visit 3, RM is given to each patient to cover the treatment till the next Visit 4. Patient is requested to bring packages with all blisters (empty blisters and blister with unused IMPs and RM) on the Visit 4.

Each patient receives a Patient diary number 2, including the doses of Pregabalin Krka or Dulsevia® (depending on randomization) from Visit 3 till Phone call 2, scales for assessing the pain and with the date of Phone call 2 (28 ± 3 days after Visit 3).

Patient is requested to bring the Patient diary on the next visit.

Information obtained at Visit 3 is input in the eCRF.

Phone call 2: 4 weeks(28 ± 3 days) after visit 3 At week 6 (28 ± 3 days after Visit 3) the investigator again calls the patient by phone and asks him or her about possible bothersome adverse events and to evaluate the pain intensity in PDPN by VAS (separate assessments of current pain intensity, average pain intensity in last 24-h and worst pain intensity in last 24-h) which is a part of Patient diary 2.

The investigator can adjust the dose of Pregabalin Krka or Dulsevia®, if necessary. If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) is NOT achieved the investigator can increase the dose and if bothersome adverse event occurs the investigator can decrease the dose to the previous dose.

The investigator also checks if the patient takes the medicines appropriately (according to investigator's instructions).

Visit 4: week 8 (42 ± 3 days after Visit 3) At Visit 4, pregnancy test for women of childbearing potential and compliance monitoring are carried out; concomitant medications are checked, vital signs are measured, pain intensity in PDPN by VAS is evaluated (separate assessments of current pain intensity, average pain intensity in last 24-h and worst pain intensity in last 24-h, average pain intensity in last 4 weeks and worst pain intensity in last 4 weeks), IMP are adjusted and assessment of adverse events is carried out. Investigator collects the Patient Diary 2. Data in Patient Diary 2 are checked.

Treatment options during PERIOD 3 (it lasts 4 weeks) ARM 1: pregabalin (Pregabalin Krka)

Investigator can choose:

Total Pregabalin Krka daily dose: 75 mg/day *,150 mg/day, 300 mg/day or 600 mg/day

*only in case of bothersome adverse events

ARM 2: duloxetine (Dulsevia®) Investigator can choose:Total Dulsevia® daily dose: 30 mg/day*, 60 mg/day, 90 mg/day or 120 mg/day *only in case of bothersome adverse events

Arm 1: pregabalin (Pregabalin Krka)

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is achieved, further treatment with previous dose in the period 3 is required.

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is NOT achieved on daily dose 150 mg, further treatment with a dose of: 150 mg/day (if patient was till now treated with equal dose) or 300 mg/day (if patient was till now treated with lower or equal dose) or 600 mg/day (if patient was till now treted with lower or equal dose) is required.

Arm 2: duloxetine (Dulsevia®)

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is achieved further treatment with previous dose in the period 3 is required.

• If average pain intensity in PDPN in last 24-h equal or below 30 mm (measured by VAS) or reduction of pain equal or more than 30 % compared with Visit 3 is NOT achieved, further treatment with a dose of:

Dulsevia® 60 mg/day (if patient was till now treated with equal dose) or Dulsevia® 90 mg/day (if patient was till now treated with lower or equal dose) or Dulsevia® 120 mg/day (if patient was till now treated with lower or equal dose).

At the Visit 4, RM is given to each patient to cover the treatment till the next Visit 5.

Visit 5: week 12 (28 ± 3 days after Visit 4) At Visit 5 investigator performs again assessments of: QoL, sleep quality and daytime sleepiness, depression, cognition and PDPN.

Evaluation of the pain intensity in PDPN by VAS and assessment of the adverse events should be performed.

Pregnancy test for women of childbearing potential is carried out.

Compliance monitoring, measurement of vital signs and concomitant medications are also carryed out by investigator.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 254
• Est. completion date: December 21, 2021
• Est. primary completion date: December 21, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Female and male patients aged 18-85 years.

2. Patients with a history of type 2 diabetes mellitus according to The American Diabetes Association (ADA).

3. Patients with a diagnosis of painful diabetic peripheral neuropathy (PDPN) caused by type 2 diabetes mellitus based on DN4 =4.

4. Patients whose average pain intensity in PDPN in last 24 hours (measured by VAS), evaluated on baseline visit, is equal or more than 40 mm (0 mm ='no pain' and 100 mm ='worst possible pain').

5. Ability to adhere to trial protocol.

6. Written informed consent.

The methods for inclusion criteria assessment include medical history, interview, completing the DN4 questionnaire, physical examination, assesment of pain on VAS and laboratory analyses.

Exclusion Criteria:

1. Patients who took PDPN medication and/or analgesics on a day of baseline visit.

2. Patients with a known hypersensitivity to duloxetine, pregabalin, paracetamol or tramadol or any of the inactive ingredients or have any contraindication for the use of duloxetine, pregabalin, paracetamol or tramadol.

3. Patients with a history of inadequate pain response (pain reduced was equal or less than 30%) to:

3.1. pregabalin at maximum allowed treatment daily dose 600 mg, 3.2. duloxetine at maximum allowed treatment daily dose 120 mg, 3.3. venlafaxine at maximum allowed treatment daily dose 375 mg, 3.4. gabapentin on daily treatment dose more than 1800 mg 3.5. amitriptilin at maximum allowed treatment daily dose 150 mg.

4. Patients, who are currently treated with a daily dose that exceeds:

4.1. 150 mg of pregabalin, 4.2. 60 mg of duloxetine, 4.3. 150 mg of venlafaxine, 4.4. 600 mg of gabapentin.

5. Patients with an uncontrolled type 2 diabetes mellitus.

6. The average scores of less than 20 on MoCA.

7. Have any other type of neuropatic pain, contrasted to PDPN.

8. Evidence of another cause of distal polyneuropathy other than diabetic.

9. Have a serious (evaluated by physician) unstable cardiovascular (e.g. uncontrolled hypertension), hepatic, renal, respiratory, ophthalmologic, gastrointestinal, or hematologic illness, symptomatic peripheral vascular disease, malignant disease or other medical condition that could lead to hospitalisation during the course of the trial.

10. Have a diagnosis or history of uncontrolled glaucoma.

11. Known or suspected alcohol or drug abuse or addiction (excluding nicotine and caffeine).

12. Patients with a history of depression (less than one year after completing the last medical treatment), mania, bipolar disorder, psychosis or schizophrenia.

13. Pregnancy, lactation and women of child-bearing potential without highly effective* or at least acceptable** contraception (according to the Recommendations related to contraception and pregnancy testing in clinical trials).

14. Patients with a history of epilepsy, stroke or neurodegenerative disease.

15. Patients taking Monoamine oxidase (MAO) inhibitors or are within one year of their withdrawal.

16. Acute liver injury (such as hepatitis) or severe cirrhosis (Child-Pugh Class C).

17. Patients with suspected Restless leg syndrome (RLS).

18. Abnormal thyroid-stimulating hormone (TSH) concentrations (according to the references value of the local laboratory).

19. Vitamin B12 and folic acid deficiency (according to the reference values of the local laboratory).

20. Surgical procedures planned to occur during trial (patients may be rescreened following completion of and recovery from the surgical procedure).

21. Concomitant treatment that might influence the final therapeutic effect of the tested active substances including non-medical treatments.

22. Patients who under the opinion of the investigator will not be compliant to the treatment or not be able to finish the trial for any other reason.

• Highly effective contraception is:

• combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation(oral, intravaginal, transdermal)

• progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)

• intrauterine device (IUD)

• intrauterine hormone-releasing system (IUS)

• bilateral tubal occlusion

• vasectomised partner

• sexual abstinence

**Acceptable contraception is:

• progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action

• male or female condom with or without spermicide

• cap, diaphragm or sponge with spermicide

Related Conditions & MeSH terms

• Diabetic Neuropathies
• Pain
• Painful Diabetic Peripheral Neuropathy
• Peripheral Nervous System Diseases

Intervention

Drug:
• Pregabalin
Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg. Duration: 12 weeks
• Duloxetine
Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg. Duration: 12 weeks

Locations

Country	Name	City	State
Croatia	Opca bolnica Karlovac	Karlovac
Croatia	Clinical Medical Center Osijek	Osijek
Croatia	KB Merkur, Sveucilišna klinika Vuk Vrhovac	Zagreb
Croatia	Klinicka bolnica Sveti Duh	Zagreb
North Macedonia	JZU Univerzitetska klinika za endokrinologija, dijabetes I metabolicki bolesti - Skopje	Skopje
North Macedonia	JZU Univerzitetska klinika za nevrologija	Skopje
Poland	Gabinet Neurologiczny, prof. Adam Stepien	Warszawa
Poland	Poradnia neurologiczna, Centrum terapii dzieci i Doroslych FIMEDICA Sp. z o.o.	Warszawa
Serbia	Klinicki centar Srbije	Belgrade
Serbia	Klinicki centar Niš	Niš
Serbia	Klinicki centar Vojvodine	Novi Sad
Slovenia	Zdravstveni dom Koper	Koper
Slovenia	Clemenz Marjetka - Nevrološka Ordinacija	Ljubljana

Sponsors (4)

Lead Sponsor	Collaborator
KRKA	3ARH, INTERBORA, University Medical Centre Maribor

Countries where clinical trial is conducted

Croatia,  North Macedonia,  Poland,  Serbia,  Slovenia, 

References & Publications (24)

Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010 Sep;17(9):1113-e88. doi: 10.1111/j.1468-1331.2010.02999.x. Epub 2010 Apr 9. Review. — View Citation

Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-8. Review. — View Citation

Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010 Oct;49(10):661-9. doi: 10.2165/11536200-000000000-00000. Review. — View Citation

Del Casale A, Girardi P, Brugnoli R, Sani G, Di Pietro S, Brugnoli C, Caccia F, Angeletti G, Serata D, Rapinesi C, Tatarelli R, Kotzalidis GD. Duloxetine in the treatment of elderly people with major depressive disorder. Riv Psichiatr. 2012 Nov-Dec;47(6):479-88. doi: 10.1708/1178.13054. Review. — View Citation

Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005 Jun;115(3):254-263. doi: 10.1016/j.pain.2005.02.032. Epub 2005 Apr 18. — View Citation

Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 Jul;116(1-2):109-18. — View Citation

Goldstein DJ. Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007 Apr;3(2):193-209. — View Citation

Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004 Dec 14;63(11):2104-10. — View Citation

Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician. 2010 Jul 15;82(2):151-8. Review. — View Citation

Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014 Jan 3;(1):CD007115. doi: 10.1002/14651858.CD007115.pub3. Review. — View Citation

Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol. 2006 Nov;21(6):311-7. Review. — View Citation

Raskin J, Pritchett YL, Wang F, D'Souza DN, Waninger AL, Iyengar S, Wernicke JF. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005 Sep-Oct;6(5):346-56. — View Citation

Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006 Sep-Oct;7(5):373-85. — View Citation

Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial. Neurosciences (Riyadh). 2014 Jul;19(3):192-8. — View Citation

Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005 Apr;6(4):253-60. — View Citation

Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004 Aug;110(3):628-638. doi: 10.1016/j.pain.2004.05.001. — View Citation

Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013 Jan;9(1):105-15. doi: 10.1517/17425255.2013.749239. Epub 2012 Dec 4. Review. — View Citation

Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother. 2005 Dec;39(12):2029-37. Epub 2005 Nov 15. — View Citation

Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag. 2007;3(6):833-44. Review. — View Citation

Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007 Jan;29(1):26-48. Review. — View Citation

Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008 Feb;12(2):203-13. Epub 2007 Jul 16. — View Citation

Wernicke JF, Prakash A, Kajdasz DK, Houston J. Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions. J Diabetes Complications. 2009 Sep-Oct;23(5):349-59. doi: 10.1016/j.jdiacomp.2008.07.004. Epub 2008 Sep 2. — View Citation

Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006 Oct 24;67(8):1411-20. — View Citation

Wernicke JF, Raskin J, Rosen A, Pritchett YL, D'Souza DN, Iyengar S, Knopp K, Le TK. Duloxetine in the long-term management of diabetic peripheral neuropathic pain: An open-label, 52-week extension of a randomized controlled clinical trial. Curr Ther Res Clin Exp. 2006 Sep;67(5):283-304. doi: 10.1016/j.curtheres.2006.10.001. — View Citation

* Note: There are 24 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinically meaningful improvement of pain in PDPN after a 12 week treatment with pregabalin	Clinically meaningful improvement of pain in PDPN after a 12 week treatment according to VAS	12 weeks
Primary	Clinically meaningful improvement of pain in PDPN after a 12 week treatment with duloxetine	Clinically meaningful improvement of pain in PDPN after a 12 week treatment according to VAS	12 weeks
Secondary	The proportion of patients with reduction of pain in PDPN for equal or more than 30 % AND/OR with pain intensity in PDPN not exceeding 30 mm	The proportion of patients with reduction of pain in PDPN (measured by VAS) for equal or more than 30 % AND/OR with pain intensity in PDPN not exceeding 30 mm (measured by VAS) taking into consideration: i. current pain intensity (measured at doctor's office); ii. average pain intensity in last 24-h; iii. worst pain intensity in last 24-h	week 1, week 2, week 6, week 8
Secondary	The proportion of patients with reduction of pain in PDPN for equal or more than 30 % AND/OR with pain intensity in PDPN not exceeding 30 mm	The proportion of patients with reduction of pain in PDPN for equal or more than 30 % (measured by VAS) AND/OR with pain intensity in PDPN not exceeding 30 mm (measured by VAS) taking into consideration: i. average pain intensity in last 4 weeks; ii. worst pain intensity in last 4 weeks	week 8, week 12
Secondary	Pain intensity difference in PDPN	Pain intensity difference in PDPN (measured by VAS) between each control visit/ phone call and the baseline value at Visit 2: i. current pain intensity (measured at doctor's office); ii. average pain intensity in last 24-h; iii. worst pain intensity in last 24-h	week 1, week 2, week 6, week 8, week 12
Secondary	Pain intensity difference in PDPN	Pain intensity difference in PDPN (measured by VAS) between Visits 4 and 5 and the baseline value at Visit 2: i. average pain intensity in last 4 weeks; ii. worst pain intensity in last 4 week	week 8, week 12
Secondary	The proportion of patients with reduction of pain in PDPN for equal or more than 50 %	The proportion of patients with reduction of pain in PDPN (measured by VAS) for equal or more than 50 % taking into consideration: i. current pain intensity (measured at doctor's office); ii. average pain intensity in last 24-h; iii. worst pain intensity in last 24-h	Baseline vs.: week 1, week 2, week 6, week 8, week 12
Secondary	The proportion of patients with reduction of pain in PDPN for equal or more than 50 %	The proportion of patients with reduction of pain in PDPN (measured by VAS) for equal or more than 50 % taking into consideration: i. average pain intensity in last 4 weeks; ii. worst pain intensity in last 4 weeks	week 8, week 12
Secondary	The proportion of patients with eliminated pain in PDPN	The proportion of patients with eliminated pain in PDPN, which includes intensity of pain in PDPN not exceeding 10 mm (measured by VAS) taking into consideration: i. current pain intensity (measured at doctor's office); ii. average pain intensity in last 24-h; iii. worst pain intensity in last 24-h	week 6, week 8, week 12
Secondary	The proportion of patients with eliminated pain in PDPN	The proportion of patients with eliminated pain in PDPN, which includes intensity of pain in PDPN not exceeding 10 mm (measured by VAS) taking into consideration: i. average pain intensity in last 4 weeks; ii. worst pain intensity in last 4 weeks	week 8, week 12
Secondary	Dose-related efficacy	Changes of efficacy according to changing of doses	week 2, week 8, week 12
Secondary	DN4 score difference	Mean changes of scores	baseline, week 12
Secondary	Quality of life (QoL) difference with 36-Item Short Form Survey Instrument (SF-36)	Mean changes of scores	baseline, week 12
Secondary	The Montreal Cognitive Assessment (MoCA) score difference for cognitive improvement	Mean changes of scores	week 1, week 12
Secondary	Insomnia severity index (ISI) difference for sleep	Mean changes of scores	baseline, week 12
Secondary	Epworth Sleepiness Scale (ESS) score for daytime sleepiness improvement	Mean changes of scores	baseline, week 12
Secondary	Major depression inventory (MDI) score difference for improvement of major depression	Mean changes of scores	baseline, week 12
Secondary	Proportion of compliant patients	Proportion of compliant patients, i.e. those having a compliance of more than 80 % at the regular therapy end visit	week 2, week 8, week 12

External Links

•   European Medicines Agency. Cymbalta: EPAR - Product information, [Accessed 2014 July14]